

Contact:

Loraine V. Upham

Lori@CureDM.com

(505-515-1947)

CureDM Announces New CEO, Loraine V. Upham

Wilmington, DE – September 7, 2016 – CureDM announces the promotion of founder and inventor, Loraine V. Upham to the position of CEO. Ms. Upham is an inventor on the seven issued patents around the CureDM therapeutic candidate, HIP2B and its uses for treatment of diabetes, and she is the original CEO. “Joe Reiser did a great job with the company over the last 8 years, and he will remain an active member of our board of directors,” states Upham, “but I am really excited to take the helm again as we continue through clinical development for both type 2 and type 1 diabetes patients.”

The company has opened an office in Albuquerque, New Mexico to accommodate the change, while keeping the corporate headquarters in Wilmington, DE. Upham explains, “New Mexico has a number of business incentives and a significant type 2 diabetes population. We look forward to pursuing our clinical program with our existing partners as well as some new potential partners in the local Albuquerque community.” HIP2B is a human derived peptide therapeutic that stimulates proteomic pathways that lead to islet neogenesis that can restore islet mass by creating new, healthy islets. Both type 1 and type 2 indications will be pursued.

About CureDM

CureDM is a biopharmaceutical company focused on the discovery and development of new therapeutics that prevent, ameliorate, or reverse diseases of metabolism. CureDM was co-founded by a molecular biologist and two endocrinologists who experienced the unmet medical need in diabetes patients on a daily basis, which provided the motivation for the discovery of HIP2B. For more information about CureDM, visit www.curedm.com.

XXXXXX